Table 3

Clinical outcomes at 180 days after follow-up echocardiography

Clinical outcome measuresNumber of patients with event/Number of patients at risk
(cumulative 180-day incidence)
HR (95% CI)
Reduction in LAD
(n=398)
No reduction in LAD
(n=275)
CrudeP valueAdjustedP value
All-cause death or hospitalisation for heart failure52/314 (13.3%)60/196 (22.2%)0.57
(0.40 to 0.81)
0.0020.59
(0.36 to 0.97)
0.04
All-cause death18/344 (4.6%)23/230 (8.6%)0.48
(0.27 to 0.85)
0.010.40
(0.18 to 0.87)
0.02
Hospitalisation for heart failure38/314 (9.9%)41/196 (15.7%)0.63
(0.41 to 0.97)
0.040.77
(0.42 to 1.44)
0.42
Cardiovascular death or hospitalisation for heart failure46/314 (11.8%)51/196 (19.2%)0.59
(0.40 to 0.87)
0.0070.73
(0.43 to 1.24)
0.24
  • The Cox proportional hazards regression model was constructed adjusting for 15 clinically relevant risk-adjusting variables: age ≥80 years, sex, atrial fibrillation/flutter, renal failure, anaemia, LVEF <40%, moderate/severe MR, LAD ≥40 mm, TRPG >31.4 mm Hg, change in TRPG >0 mm Hg, LVDd >55 mm, change in LVDd >0 mm, ACE-I or ARB, β-blockers and MRA.

  • ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; LAD, left atrial diameter; LVDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; TRPG, tricuspid regurgitation pressure gradient.